Answers are grounded in this paper and cite their sources.
This review summarizes the evidence base for angiotensin receptor antagonists, focusing on candesartan cilexetil for the treatment of arterial hypertension.
Arterial hypertension (AH) remains the one of the major cardiovascular diseases in the adult population and a major factor in cardiovascular and cerebrovascular morbidity and mortality. Drug therapy of hypertension leads to a reduction of cardiovascular risk by affecting blood pressure. Renin-angiotensin-aldosterone system (RAAS) plays a key role in the formation of hypertension, as the drug blockade of its components can significantly improve the prognosis of patients. The principal means of blocking the RAAS are angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists II (ARA II, sartans). Both classes of drugs have shown their high antihypertensive efficacy, with the ARA II having almost perfect portability. Recently, however, sartans’independent rolein the treatment of hypertension has been questioned. Date overview of the evidence base of sartans with a focus on modern antihypertensive drug called candesartan cilexetil was the following work’s objective.
No takes yet. Share an insight, caveat, or question.
Барбараш et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: